Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David V Sheehan

Showing results (31-40 of 81) with videos related to

Pageof 9
Sort By:
Innovations in Clinical Neuroscience|June 4, 2011
The use of research measures in adult clinical practiceJoan Busner, Stuart L Kaplan, Nicholas Greco, et al.
Psychopharmacology Bulletin|June 29, 2010
The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorderDavid V Sheehan, Anna Rozova, E Roderich Gossen, et al.
Journal of Clinical Psychopharmacology|September 7, 2004
Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetineDavid V Sheehan, Michael Eaddy, Matthew Sarnes, et al.
Psychopharmacology Bulletin|November 17, 2007
An open-label study of tiagabine in panic disorderDavid V Sheehan, Kathy Harnett Sheehan, B Ashok Raj, et al.
The Journal of Clinical Psychiatry|January 27, 2005
Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorderDavid V Sheehan, Daniel B Burnham, Malini K Iyengar, et al.
International Clinical Psychopharmacology|February 25, 2009
Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic featuresDavid V Sheehan, Charles B Nemeroff, Michael E Thase, et al.
The American Journal of Managed Care|October 21, 2005
Differences in total medical costs across the SSRIs for the treatment of depression and anxietyDavid V Sheehan, Michael T Eaddy, Manan B Shah, et al.
Journal of Affective Disorders|April 2, 2017
Restoring function in major depressive disorder: A systematic reviewDavid V Sheehan, Kazuyuki Nakagome, Yuko Asami, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 18, 2012
Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trialLeszek Bidzan, Atul R Mahableshwarkar, Paula Jacobsen, et al.
Psychiatry (Edgmont (Pa. : Township))|September 3, 2009
Sheehan Suicidality Tracking Scale (Sheehan-STS): Preliminary Results from a Multicenter Clinical Trial in Generalized Anxiety DisorderVladimir Coric, Elyse G Stock, Joseph Pultz, et al.
Pageof 9

Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Innovations in Clinical Neuroscience|June 4, 2011
The use of research measures in adult clinical practiceJoan Busner, Stuart L Kaplan, Nicholas Greco, et al.
Psychopharmacology Bulletin|June 29, 2010
The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorderDavid V Sheehan, Anna Rozova, E Roderich Gossen, et al.
Journal of Clinical Psychopharmacology|September 7, 2004
Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetineDavid V Sheehan, Michael Eaddy, Matthew Sarnes, et al.
Psychopharmacology Bulletin|November 17, 2007
An open-label study of tiagabine in panic disorderDavid V Sheehan, Kathy Harnett Sheehan, B Ashok Raj, et al.
The Journal of Clinical Psychiatry|January 27, 2005
Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorderDavid V Sheehan, Daniel B Burnham, Malini K Iyengar, et al.
International Clinical Psychopharmacology|February 25, 2009
Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic featuresDavid V Sheehan, Charles B Nemeroff, Michael E Thase, et al.
The American Journal of Managed Care|October 21, 2005
Differences in total medical costs across the SSRIs for the treatment of depression and anxietyDavid V Sheehan, Michael T Eaddy, Manan B Shah, et al.
Journal of Affective Disorders|April 2, 2017
Restoring function in major depressive disorder: A systematic reviewDavid V Sheehan, Kazuyuki Nakagome, Yuko Asami, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 18, 2012
Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trialLeszek Bidzan, Atul R Mahableshwarkar, Paula Jacobsen, et al.
Psychiatry (Edgmont (Pa. : Township))|September 3, 2009
Sheehan Suicidality Tracking Scale (Sheehan-STS): Preliminary Results from a Multicenter Clinical Trial in Generalized Anxiety DisorderVladimir Coric, Elyse G Stock, Joseph Pultz, et al.
Pageof 9